Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2020 1
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Multiparametric chemical exchange saturation transfer MRI detects metabolic changes in breast cancer following immunotherapy.
Hoffmann E, Schache D, Höltke C, Soltwisch J, Niland S, Krähling T, Bergander K, Grewer M, Geyer C, Groeneweg L, Eble JA, Vogl T, Roth J, Heindel W, Maus B, Helfen A, Faber C, Wildgruber M, Gerwing M, Hoerr V. Hoffmann E, et al. Among authors: krahling t. J Transl Med. 2023 Aug 28;21(1):577. doi: 10.1186/s12967-023-04451-6. J Transl Med. 2023. PMID: 37641066 Free PMC article.
Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy.
Hoffmann E, Gerwing M, Krähling T, Hansen U, Kronenberg K, Masthoff M, Geyer C, Höltke C, Wachsmuth L, Schinner R, Hoerr V, Heindel W, Karst U, Eisenblätter M, Maus B, Helfen A, Faber C, Wildgruber M. Hoffmann E, et al. Among authors: krahling t. Breast Cancer Res. 2023 May 23;25(1):56. doi: 10.1186/s13058-023-01658-9. Breast Cancer Res. 2023. PMID: 37221619 Free PMC article.
Multiparametric MRI enables for differentiation of different degrees of malignancy in two murine models of breast cancer.
Gerwing M, Hoffmann E, Kronenberg K, Hansen U, Masthoff M, Helfen A, Geyer C, Wachsmuth L, Höltke C, Maus B, Hoerr V, Krähling T, Hiddeßen L, Heindel W, Karst U, Kimm MA, Schinner R, Eisenblätter M, Faber C, Wildgruber M. Gerwing M, et al. Among authors: krahling t. Front Oncol. 2022 Nov 2;12:1000036. doi: 10.3389/fonc.2022.1000036. eCollection 2022. Front Oncol. 2022. PMID: 36408159 Free PMC article.
Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease.
Gerwing M, Krähling T, Schliemann C, Harrach S, Schwöppe C, Berdel AF, Klein S, Hartmann W, Wardelmann E, Heindel WL, Lenz G, Berdel WE, Wildgruber M. Gerwing M, et al. Among authors: krahling t. Cancers (Basel). 2021 Nov 23;13(23):5880. doi: 10.3390/cancers13235880. Cancers (Basel). 2021. PMID: 34884988 Free PMC article.
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.
Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE. Schliemann C, et al. Among authors: krahling t. Cancers (Basel). 2020 Jun 7;12(6):1488. doi: 10.3390/cancers12061488. Cancers (Basel). 2020. PMID: 32517329 Free PMC article.